Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyFri, 16 Aug 2024 02:32:26 +0200Fri, 12 Jul 2024 17:16:13 +0200Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0282/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip11-23Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0282/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip11-23Fri, 12 Jul 2024 17:16:13 +0200Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0201/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip10-23Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0201/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip10-23Fri, 05 Jul 2024 16:29:18 +0200Human medicine